Association of COVID-19 with New-Onset Alzheimer’s Disease
An infectious etiology of Alzheimer’s disease has been postulated for decades. It remains unknown whether SARS-CoV-2 viral infection is associated with increased risk for Alzheimer’s disease.
Project FluCov: understanding and communicating the impact of COVID-19 on influenza activity
Nivel is researching the impact of COVID-19 on Influenza activity combining data from around the world.
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined.
International community will gather in Brussels to discuss pandemic preparedness
Next Tuesday 21 June, the European Scientific Working group on Influenza (ESWI) will host a summit on the continuing pandemic threat posed by respiratory viruses, entitled “Pandemic Preparedness: Where Science and Policy Meet”.
9th Congress of the European Academy of Paediatric Societies
October 7-11 2022, Barcelona and online
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model
In this human infection challenge pilot study, adults aged 18–55 years and 60–75 years were assessed for enrolment using protocol-defined inclusion and exclusion criteria.
World Influenza Conference
September 17-18 2022, Shenzen China - Virtual
Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial
High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above.